VABC and Bradmer Pharmaceuticals co-hosted a symposium on trends in Glioblastoma Multiforme (GBM) treatment and therapeutic advancements to the brightest minds in brain cancer research and treatment in November 2008 in New York City.
The expert panel included Chair Steven Rosenfeld, MD (Columbia University Medical Center); Henry Friedman, MD (Duke University Medical Center);Keith Black, MD (Cedars-SinaiMedical Center); Pamela New, MD (Methodist Neurological Institute); David A. Reardon, MD (Duke University Medical Center); Michael R. Zalutsky, PhD (Duke University Medical Center); and Alan M. Ezrin, PhD (President & CEO, Bradmer Pharmaceuticals).
Topic discussed included current trends in treatment of GBM (history and epidemiology, current standard of care, opportunities for protocol advancement) and therapeutic advancements for GBM (current class of pre-approval compounds, novel protocols, outlook for patients.)
This discussion stimulated innovative thinking and collaborative efforts in brain cancer treatment.
If you are interested in sponsoring a VABC event or would like to serve on the Event Committee, please contact Darren Port at 646.278.6735.